High materiality7/10
Moderna price target raised to $150 from $50 at UBS
Why it may matterVerify against the original reporting
Downside risk implied by PT below current price
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
UBS raises MRNA target to $150; current price reported at $174.38.
- UBS raises MRNA PT to $150 (below current price)
- Current price: $174.38
Key facts
- 01
Target: $150
- 02
Posted price: $174.38
- 03
Analyst firm: UBS
- 04
Analyst: Michael Yee
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.